These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4;14): The MD Anderson Cancer Center Experience. Pasvolsky O; Gaballa MR; Milton DR; Masood A; Sami SS; Tanner MR; Bashir Q; Srour S; Saini N; Ramdial J; Nieto Y; Tang G; Lin P; Lee HC; Patel KK; Kebriaei P; Thomas SK; Weber DM; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH Transplant Cell Ther; 2023 Apr; 29(4):260.e1-260.e6. PubMed ID: 36646323 [TBL] [Abstract][Full Text] [Related]
6. Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial. Oliva S; Bruinink DHO; Rihova L; D'Agostino M; Pantani L; Capra A; van der Holt B; Troia R; Petrucci MT; Villanova T; Vsianska P; Jugooa R; Brandt-Hagens C; Gilestro M; Offidani M; Ribolla R; Galli M; Hajek R; Gay F; Cavo M; Omedé P; van der Velden VHJ; Boccadoro M; Sonneveld P Blood Cancer J; 2021 Jun; 11(6):106. PubMed ID: 34083504 [TBL] [Abstract][Full Text] [Related]
7. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study. Rawstron AC; Child JA; de Tute RM; Davies FE; Gregory WM; Bell SE; Szubert AJ; Navarro-Coy N; Drayson MT; Feyler S; Ross FM; Cook G; Jackson GH; Morgan GJ; Owen RG J Clin Oncol; 2013 Jul; 31(20):2540-7. PubMed ID: 23733781 [TBL] [Abstract][Full Text] [Related]
8. Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics. Chakraborty R; Muchtar E; Kumar SK; Jevremovic D; Buadi FK; Dingli D; Dispenzieri A; Hayman SR; Hogan WJ; Kapoor P; Lacy MQ; Leung N; Gertz MA Biol Blood Marrow Transplant; 2017 Apr; 23(4):598-605. PubMed ID: 28115277 [TBL] [Abstract][Full Text] [Related]
9. Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial. Diamond B; Korde N; Lesokhin AM; Smith EL; Shah U; Mailankody S; Hultcrantz M; Hassoun H; Lu SX; Tan C; Rustad EH; Maura F; Maclachlan K; Peterson T; Derkach A; Devlin S; Landau HJ; Scordo M; Chung DJ; Shah GL; Lahoud O; Thoren K; Murata K; Ramanathan L; Arcila ME; Ho C; Roshal M; Dogan A; Giralt SA; Landgren O Lancet Haematol; 2021 Jun; 8(6):e422-e432. PubMed ID: 34048681 [TBL] [Abstract][Full Text] [Related]
10. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Paiva B; Vidriales MB; Cerveró J; Mateo G; Pérez JJ; Montalbán MA; Sureda A; Montejano L; Gutiérrez NC; García de Coca A; de Las Heras N; Mateos MV; López-Berges MC; García-Boyero R; Galende J; Hernández J; Palomera L; Carrera D; Martínez R; de la Rubia J; Martín A; Bladé J; Lahuerta JJ; Orfao A; San Miguel JF; Blood; 2008 Nov; 112(10):4017-23. PubMed ID: 18669875 [TBL] [Abstract][Full Text] [Related]
11. [Impact of minimal residual disease detection after treatment of multiple myeloma]. Szendrei T; Plander M; Szabó Z; Kereskai L; Kajtár B; Papp G; Iványi JL Orv Hetil; 2019 Mar; 160(13):502-508. PubMed ID: 30907098 [TBL] [Abstract][Full Text] [Related]
12. Achieving minimal residual disease-negative by multiparameter flow cytometry may ameliorate a poor prognosis in MM patients with high-risk cytogenetics: a retrospective single-center analysis. Li H; Li F; Zhou X; Mei J; Song P; An Z; Zhao Q; Guo X; Wang X; Zhai Y Ann Hematol; 2019 May; 98(5):1185-1195. PubMed ID: 30721336 [TBL] [Abstract][Full Text] [Related]
13. Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response. Mina R; Petrucci MT; Corradini P; Spada S; Patriarca F; Cerrato C; De Paoli L; Pescosta N; Ria R; Malfitano A; Musto P; Baldini L; Guglielmelli T; Gamberi B; Mannina D; Benevolo G; Zambello R; Falcone AP; Palumbo A; Nagler A; Calafiore V; Hájek R; Spencer A; Boccadoro M; Bringhen S Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):533-540. PubMed ID: 29910180 [TBL] [Abstract][Full Text] [Related]
14. Minimal residual disease negativity and lenalidomide maintenance therapy are associated with superior survival outcomes in multiple myeloma. Patel DA; Gopalakrishnan R; Engelhardt BG; McArthur E; Sengsayadeth S; Culos KA; Byrne M; Goodman S; Savani BN; Chinratanalab W; Jagasia M; Mosse CA; Cornell RF; Kassim AA Bone Marrow Transplant; 2020 Jun; 55(6):1137-1146. PubMed ID: 31992845 [TBL] [Abstract][Full Text] [Related]
15. [The prognostic value of dynamic minimal residual disease after autologous hematopoietic stem cell transplantation in patients with multiple myeloma in novel-agent era]. Yang GZ; Wang GR; Wang HJ; Zhang YR; Wu Y; Li YC; Liu AJ; Leng Y; Gao W; Chen WM Zhonghua Yi Xue Za Zhi; 2022 Aug; 102(30):2345-2350. PubMed ID: 35970792 [No Abstract] [Full Text] [Related]
16. Impact of pretransplant minimal residual disease in patients with multiple myeloma and a very good partial response or better receiving autologous hematopoietic stem cell transplantation. Pasvolsky O; Pasyar S; Bassett RL; Khan HN; Tanner MR; Bashir Q; Srour S; Saini N; Lin P; Ramdial J; Nieto Y; Lee HC; Patel KK; Kebriaei P; Thomas SK; Weber DM; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH Cancer; 2024 May; 130(9):1663-1672. PubMed ID: 38127583 [TBL] [Abstract][Full Text] [Related]
17. Minimal residual disease and log-reduction of plasma cells are associated with superior response after double autologous stem cell transplant in younger patients with multiple myeloma. Rossi G; Falcone AP; Minervini MM; De Cillis GP; De Waure C; Sisti LG; Giambra V; Valente D; Chiello V; Scalzulli PR; Carella AM; Cascavilla N Cytometry B Clin Cytom; 2019 May; 96(3):195-200. PubMed ID: 30549231 [TBL] [Abstract][Full Text] [Related]
18. Utility and feasibility of a six-color multiparametric flow cytometry for measurable residual disease analysis in plasma cell myeloma in resource-limited settings with 5-year survival data. Sharma P; Singh Sachdeva MU; Varma N; Bose P; Aggarwal R; Malhotra P J Cancer Res Ther; 2021; 17(6):1515-1520. PubMed ID: 34916387 [TBL] [Abstract][Full Text] [Related]
19. Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma. Maffini E; Storer BE; Sandmaier BM; Bruno B; Sahebi F; Shizuru JA; Chauncey TR; Hari P; Lange T; Pulsipher MA; McSweeney PA; Holmberg L; Becker PS; Green DJ; Mielcarek M; Maloney DG; Storb R Haematologica; 2019 Feb; 104(2):380-391. PubMed ID: 30262560 [TBL] [Abstract][Full Text] [Related]
20. Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent: A Phase 2 Measurable Residual Disease-Adapted Study. Derman BA; Kansagra A; Zonder J; Stefka AT; Grinblatt DL; Anderson LD; Gurbuxani S; Narula S; Rayani S; Major A; Kin A; Jiang K; Karrison T; Jasielec J; Jakubowiak AJ JAMA Oncol; 2022 Sep; 8(9):1278-1286. PubMed ID: 35862034 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]